Sorafenib Combined With Arsenical in Treating Patients With Recurrent HCC After Liver Transplantation
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
To analyze the safety, efficacy and pharmacokinetic characteristics of sorafenib combined
with compound huangdai tablets in patients with recurrent hepatocellular carcinoma after
liver transplantation